Core Viewpoint - Novavax Inc. reported a significant improvement in its financial performance for the fourth quarter and full year of 2025, with shares rising following the announcement [1]. Financial Performance - The company reported fourth-quarter earnings of 11 cents, a notable recovery from a loss of 51 cents in the same quarter last year [2]. - Revenue for the fourth quarter reached $147 million, reflecting a 67% year-over-year increase [2]. Cost Management - Novavax exceeded its 2025 cost-cutting targets for both GAAP and Non-GAAP R&D and SG&A spending, and is tightening future expense goals [2]. - The company now anticipates Non-GAAP R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 [3]. Management Commentary - The President and CEO of Novavax highlighted significant progress in corporate strategy, including achievements under the Sanofi agreement and advancements in R&D efforts [4]. Revenue Guidance - Novavax provided a revenue forecast for 2026, projecting adjusted total revenue between $230 million and $270 million, which is below the consensus estimate of $381.22 million [5]. - The company expects Nuvaxovid product sales to be between $35 million and $45 million, along with adjusted supply sales of $40 million to $50 million [5]. Technical Analysis - The stock is currently trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength [6]. - Over the past 12 months, shares have shown significant growth and are closer to their 52-week highs, reflecting a strong upward trend [6]. Momentum Indicators - The RSI is at 44.45, indicating neutral territory, suggesting the stock is neither overbought nor oversold [7]. - The absence of significant MACD crossovers indicates a stable trend without immediate bullish or bearish pressure [7]. Analyst Consensus - The stock carries a Hold Rating with an average price target of $32.23 [8]. - Recent analyst actions include a Buy rating from BTIG with a target of $19.00, while JP Morgan has an Underweight rating with a lowered target of $6.00 [8].

Group 1 - Moderna has submitted a regulatory filing to the FDA for an updated version of its COVID-19 vaccine Spikevax, targeting the LP.8.1 variant [1] - The FDA's recent guidance recommends vaccine-makers to update their COVID-19 shots to target strains from the JN.1 lineage, with a preference for LP.8.1, which currently accounts for about 70% of total cases in the U.S. [2] - The FDA has also mandated that vaccine makers conduct randomized, placebo-controlled clinical studies to demonstrate the real-world benefits of yearly COVID-19 vaccine boosters for individuals under 65 years [3] Group 2 - Year to date, Moderna's stock has decreased by 37%, while the industry has seen a decline of 6% [4] - Other COVID-19 vaccines in the market include Pfizer/BioNTech's Comirnaty and Novavax's Nuvaxovid, with no recent updates from these companies regarding their vaccines [6] - Currently, only Moderna and Pfizer/BioNTech's vaccines are approved for individuals aged six months and above, while Novavax's vaccine is restricted to specific age groups and conditions [7]